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Introduction: In septic shock patients, the prevalence of low (<70%) central venous oxygen saturation (ScvO2) on
admission to the intensive care unit (ICU) and its relationship to outcome are unknown. The objectives of the
present study were to estimate the prevalence of low ScvO2 in the first hours of ICU admission and to assess its
potential association with mortality in patients with severe sepsis or septic shock.
Methods: This was a prospective, multicentre, observational study conducted over a one-year period in ten French
ICUs. Clinicians were asked to include patients with severe sepsis or septic shock preferably within 6 hours of ICU
admission and as soon as possible without changing routine practice. ScvO2 was measured at inclusion and 6 hours
later (H6), by blood sampling.
Results: We included 363 patients. Initial ScvO2 below 70% was present in 111 patients and the pooled estimate
for its prevalence was 27% (95% Confidence interval (95%CI): 18% to 37%). At time of inclusion, among 166
patients with normal lactate concentration (≤2 mmol/L), 55 (33%) had a low initial ScvO2 (<70%), and among 136
patients who had already reached the classic clinical endpoints for mean arterial pressure (≥65 mmHg), central
venous pressure (≥8 mmHg), and urine output (≥0.5 mL/Kg of body weight), 43 (32%) had a low initial ScvO2
(<70%). Among them, 49% had lactate below 2 mmol/L. The day-28 mortality was higher in case of low initial
ScvO2 (37.8% versus 27.4%; P = 0.049). When adjusted for confounders including the Simplified Acute Physiology
Score and initial lactate concentration, a low initial ScvO2 (Odds ratio (OR) = 3.60, 95%CI: 1.76 to 7.36; P = 0.0004)
and a low ScvO2 at H6 (OR = 2.18, 95%CI: 1.12 to 4.26; P = 0.022) were associated with day-28 mortality by logistic
regression.
Conclusions: Low ScvO2 was common in the first hours of admission to the ICU for severe sepsis or septic shock
even when clinical resuscitation endpoints were achieved and even when arterial lactate was normal. A ScvO2
below 70% in the first hours of ICU admission and six hours later was associated with day-28 mortality.* Correspondence: thierry.boulain@chr-orleans.fr
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Central venous oxygen saturation (ScvO2) has long
been studied as a prognostic marker and resuscitation
end-point in patients with shock [1]. It is an imperfect
surrogate of mixed venous oxygen saturation (SvO2)
because it reflects the oxygen supply-to-consumption
ratio of the upper part of the body only. However, ScvO2 is
simple to measure either continuously or intermittently,
and spontaneous or therapy-induced changes in ScvO2
and SvO2 are closely correlated [2].
Based on these principles, Rivers et al. [3] showed that
an early therapeutic strategy that includes aiming for the
rapid normalization of ScvO2 (≥70%) in patients suffering
from severe sepsis or septic shock at presentation to the
emergency department could improve survival. Since
then, international guidelines have recommended targeting
ScvO2 at ≥70% during the first 6 hours of care in patients
presenting with severe sepsis or septic shock [4]. However,
this recommendation remains controversial. Indeed,
resuscitation protocols including an ScvO2 target have
been mostly tested in the emergency department
[5-7], not after ICU admission. Importantly, after ICU
admission, targeting normal ScvO2 is deemed to have
little place, as ScvO2 is frequently considered to be
already normalized on ICU admission [8]. However, the
prevalence of low ScvO2 (<70%) in ICU septic patients
is poorly known. It has been assessed only in two
prospective studies of limited size [9,10], while other
studies have only reported the mean initial value of
ScvO2 [8,11]. In addition, the relationship between low
ScvO2 and outcome is still unknown.
Since the Rivers study [3], the idea that the relationship
between low ScvO2 and fatal outcome in septic patients
has been widely demonstrated has remained. Up to now,
however, such a relationship has not been demonstrated in
multicentre prospective studies performed either in the
emergency department [12] or in the ICU [10]. Accordingly,
the aim of the present multicentre observational prospective
study was to estimate the prevalence of low ScvO2 in
patients presenting with severe sepsis or septic shock after
ICU admission, and to assess its potential association
with outcome.
Materials and methods
The study took place in 10 French medical-surgical adult
ICUs (4 university hospitals, 1 regional and teaching
hospital, and 5 general hospitals) with a combined total
of 154 ICU beds. Participating ICUs were asked to screen
consecutive patients presenting with sepsis and circulatory
failure for potential inclusion in the study, over a period
left at their discretion, from July 2011 to June 2012.
Clinicians were asked to include patients with severe
sepsis or septic shock, preferably within 6 hours of ICU
admission, and as soon as possible without changingroutine practice. Patients were included if they had
circulatory failure of septic origin (that is, severe sepsis or
septic shock [13]) within 12 hours after ICU admission,
and had an intra-arterial and superior vena cava (internal
jugular or subclavian) catheter in situ. Circulatory failure
was defined by either the use of vasopressor (septic shock)
or, in case of severe sepsis, by a mean arterial pres-
sure <65 mmHg or a systolic arterial pressure <90 mmHg
at least twice over a 15-minute period, associated with at
least one condition reflecting tissue hypoperfusion or low
flow state (see Table 1, Criteria for circulatory failure at
inclusion). Patients were not included in the case of brain
death, admission following cardiac arrest, or if imminent
death was expected.
Measurements and data collection
The measurement of ScvO2 was performed as soon as
possible (at the time defined as zero hours (H0)) by
sampling blood from the superior vena cava through the
central venous catheter, and at 6 hours after inclusion
(H6). ScvO2 was either calculated from blood gas analysis
by a standard blood gas analyser in four centres, or
measured by a co-oximeter in six centres. Concomitantly,
arterial blood was drawn at each time point for blood gas
analysis and lactate measurement. Other demographic,
clinical and laboratory data prospectively recorded are
provided in Additional file 1. Independent data monitoring
was conducted in each site to ascertain the accuracy
of recorded information.
The Ethics Committee of the teaching hospital of
Limoges, France, approved the protocol for all hospitals
involved (agreement number 65-2011-11) and waived the
need for prior informed consent because the study proce-
dures fulfilled the criteria of a non-interventional study as
defined by the French Law [17]. Patients’ next-of-kin and
then patients themselves if they regained capacity were
informed of their participation and their right to refuse the
use of the obtained data was clearly established.
Haemodynamic monitoring and treatment of shock
followed international [18] and national guidelines [19]
that corresponded to standard of care of the participating
centres. However, none of the participating ICUs had
implemented systematic treatment algorithms based on
ScvO2 monitoring.
Study objective
The study primary objective was to estimate the prevalence
of low ScvO2 (<70%, but other thresholds were also tested)
and to assess the possible association between low ScvO2
and day-28 mortality.
Data reporting and statistical analysis
Categorical data are expressed as percentages, and
continuous variables are expressed as means ± SD or
Table 1 Demographics, clinical characteristics, treatment
and outcome in 363 patients
Variable Value
Male sex 231 (63.6)
Age, years 65.8 ± 14.1
Severe sepsis at inclusion 25 (6.9)
Septic shock at inclusion 338 (93.1)





Skin, bones, joints 30 (8.3)
Catheter 7 (1.9)
Central nervous system 6 (1.7)
Endocarditis 6 (1.7)
Other 8 (2.2)
Source not identified 11 (3.0)
Underlying disease
Chronic obstructive pulmonary disease 63 (17.4)
Arterial hypertension 198 (54.5)
Chronic heart failure 36 (9.9)
Liver cirrhosis 27 (7.4)
Chronic haemodialysis 8 (2.2)
Type 1 diabetes 15 (4.1)
Type 2 diabetes 85 (23.4)
Immunocompromized state 110 (30.3)
Active solid cancer 45 (12.4)
Active lymphoma or leukaemia 22 (6.1)
Myeloproliferative syndrome 12 (3.3)
Recent (<6 months) chemotherapy or radiotherapy 42 (11.6)
Neutropenia (absolute neutrophil count <1,000/mm3) 27 (7.4)
HIV seropositivity 4 (1.1)
Solid organ or bone marrow transplantation 6 (1.7)
Steroids therapy 41 (11.3)
Other immunosuppressive therapy 14 (3.9)
Criteria for circulatory failure at inclusion
(in addition to recent or ongoing hypotension)
Tachycardia (heart rate >110 beats/minute) 195 (53.7)
Urine output <0.5 mL/hour per Kg of body weight 147 (40.5)
Capillary refill time >2 seconds 48 (13.2)
Cyanosis in the absence of severe hypoxemia 56 (15.4)
Skin mottling 167 (46.0)
Altered consciousness 77 (21.2)
Arterial lactate >2 mmol/L on admission 190 (52.3)
Epinephrine or norepinephrine administration 338 (93.1)
Table 1 Demographics, clinical characteristics, treatment
and outcome in 363 patients (Continued)
Therapy
Invasive mechanical ventilation on admission 128 (35.2)
Invasive mechanical ventilation during ICU stay 305 (84.0)
Norepinephrine on admission 136 (37.5)
Epinephrine on admission 10 (2.8)
Norepinephrine or epinephrine during ICU stay 356 (98.1)
Dobutamine on admission 12 (3.3)
Transfusion of blood products between zero
hours and 24 hours
58 (16.6)
Renal replacement therapy during ICU stay 84 (23.1)









Simplified acute physiology score II [15] 56.8 ± 20.0
SOFA score [16] (highest value from H0 to H24) 10.3 ± 3.4
ICU death 102 (28.1)
Day-28 death 111 (30.6)
Categorical variables are expressed as absolute counts (%) and continuous
variables as mean ± SD unless otherwise specified. aInitial arterial blood lactate
concentration was available in 358/363 patients (not measured in 5 patients
because of technical problem). SOFA, Sequential organ failure assessment.
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95% CI of ScvO2 < 70% was estimated taking into
account participating centres as a random effect [20].
The ScvO2 < 70% and other thresholds of initial ScvO2
values determined by locally weighted scatterplot
smoothing (LOWESS) [21] were examined for their
potential association with day-28 mortality.
Each given threshold of the initial ScvO2 value was
entered in a mixed-effect logistic regression model, with
participating centres entered as a random effect, and
adjusted for all covariables available at H0 and linked
to day-28 mortality with a P-value <0.15, by univariate
analysis. The covariables were eliminated using the
backward method until the final logistic model with
the best fit (as assessed by the Akaike information
criterion [15]) was reached. Based on the results of a
retrospective study performed in one participating ICU
[22], we calculated that 1-year study duration would
allow the inclusion of at least 350 patients with 100
fatalities, which would allow multivariate evaluation
of ten covariables, including ScvO2.
We re-ran the logistic analyses in predefined subgroups
of patients (for example, mechanical ventilation or not at
H0, patients below or above median values of continuous
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expansion before inclusion, et cetera).
Percentages were compared using the Fisher exact test,
chi-square test, or chi-square test for trend (Cochran-
Armitage test), and continuous variables were compared
using the unpaired Student t-test or by analysis of vari-
ance when appropriate. Unadjusted comparisons of sur-
vival curves were performed using the log-rank test.
Adjusted odds ratios (OR) are given with the 95% CI. A
two-tailed P-value <0.05 was considered statistically sig-
nificant. Mixed-effect logistic regression was performed
using the lme4 package of R 2.15.2 [23].Results
We screened 670 patients with severe sepsis or septic
shock. Among them, 363 patients were enrolled (Figure 1).
The Simplified acute physiology score (SAPSII) [24] and
ICU death rates were similar in enrolled and non enrolled
patients (see Additional file 2).
Demographic and clinical characteristics are shown in
Table 1. The median time between ICU admission and
inclusion (H0), and between the time at which criteria
for inclusion were satisfied and inclusion, was 211 mi-
nutes (IQR 83 to 339) and 189 minutes (IQR 84 to 292),
respectively. The median time between severe sepsis
identification and inclusion (H0) was 7.6 hours (IQR 2
to 13.2). Details of resuscitation administered before in-
clusion and time of inclusion in patients classified ac-
cording to their origin (transferred from another
hospital, from the ward, or from the emergency depart-
ment) are shown in Table 2.
The mean initial ScvO2 value was 74.1 ± 11.0% and was
not different between survivors and non survivors at day 28
(74.6 ± 10.0% versus 73.0 ± 12.9%, respectively; P = 0.21).Prevalence of low initial ScvO2
Initial ScvO2 < 70% was present in 111 patients and the
pooled estimate for its prevalence, taking into account
participating centres as a random effect, was 27%
(95% CI 18%, 37%). At H0, 136 patients (37%) had reached
the classic clinical endpoints for mean arterial pressure
(≥65 mmHg), central venous pressure (≥8 mmHg), and
urine output (≥0.5 mL/Kg of body weight). Among them,
32% (43/136) had an initial ScvO2 < 70%, with normal
lactate concentration (≤2 mmol/L) in 21 (49%) patients. At
H0, 166 patients (46%) had normal lactate concentration
(≤2 mmol/L). Among them, 55 (33%) had an initial
ScvO2 < 70%. The delay between severe sepsis identification
and inclusion and the amount of fluids administered for
resuscitation before inclusion had no influence on the mean
initial ScvO2 values or on the proportions of patients with
initial ScvO2 < 70% (see Additional file 3).Crude day-28 death rate and initial ScvO2 level
As determined by visual inspection of the LOWESS
plot (see Additional file 4), we assessed the associ-
ation between day-28 mortality and initial ScvO2 <
70%, <75%, and >85%. The day-28 death rate was sig-
nificantly higher in patients with initial ScvO2 < 70%
than in patients with initial ScvO2 ≥ 70% (42/111
(37.8%) versus 69/252 (27.4%), respectively; P = 0.049),
whereas it was similar in patients with initial ScvO2
below or above the other thresholds examined (all
P-values >0.35) (see Additional file 5: Table E8).
Association between ScvO2 and mortality when adjusted
for potential confounders
The initial ScvO2 entered in the logistic model as a
continuous variable was negatively linked to day-28
mortality: OR = 0.96 (95% CI 0.93, 0.99) for each 1%
increase in initial ScvO2; P = 0.004 (see Additional file
5: Table E9). An initial ScvO2 < 70% was significantly
and independently associated with day-28 mortality
(OR = 3.60, 95%CI 1.76, 7.36; P = 0.0004) (Table 3), a
trend consistently observed across the different
subgroups examined (Figure 2).
An initial ScvO2 < 75% was also significantly associated
with day-28 mortality (OR = 2.15, 95% CI 1.16 to 3.98;
P = 0.015) (see Additional file 5: Table E10).
Evolution of ScvO2 and relationship to lactate
concentration
The evolution of ScvO2 between H0 and H6 was similar
between survivors and non survivors on day 28 (see
Additional file 6: Figure E3). However, by logistic regres-
sion analysis, a ScvO2 < 70% at H6 still appeared as a risk
factor for day-28 death (OR = 2.18, 95% CI 1.12, 4.26;
P = 0.022) (see Additional file 5: Table E11).
The proportion of patients with initial ScvO2 < 70%
was similar in the case of lactate above or below the me-
dian initial lactate value of 2.2 mmol/L (29% versus 33%;
P = 0.3). Figure 3 shows the survival curves and the crude
death rates at day 28 in four patients’ subgroups according
to their lactate concentration and ScvO2 at H0 (for
subgroups according to lactate and ScvO2 at H6 see
Additional file 6: Figure E4). In subgroup analysis, the
logistic regression showed that ScvO2 < 70% was independ-
ently associated with day-28 death in patients with initial
lactate level <2.2 mmol/L (OR = 3.31) (Figure 2).
Among the 335 patients with lactate and ScvO2
measured at H0 and H6, 148 (44%) had a satisfactory
lactate clearance (defined as at least a 10% decrease
between H0 and H6 [25]) and 187 (56%) had not.
The proportion of patients with ScvO2 < 70% at H6
was similar in the case of satisfactory or not satisfac-
tory lactate clearance (22% versus 23%, respectively).
Additional file 6: Figure E5 shows the survival curves
Figure 1 Flow diagram.
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subgroups according to their lactate clearance and
ScvO2 at H0 and H6. On logistic regression, ScvO2 <
70% at H6 was independently associated with day-28
mortality in the subgroup of patients with non satis-
factory lactate clearance (OR = 2.32 (1.03, 5.23)) butnot in patients with satisfactory lactate clearance
(OR = 0.98 (0.21, 4.54)). Additional results for the
roles played by initial respiratory conditions, haemo-
globin concentration and body temperature in the
prevalence of low ScvO2 and mortality are given in
Additional file 7.







(n = 93) (n = 95) (n = 175)
Patients intubated before inclusion 73 (78%) 72 (77%) 118 (67%)
Amount of fluid administered before inclusion, mL/Kg
of body weight
31 35 36
(12 to 50) (19 to 51) (20 to 52)
Patients treated with vasopressors before inclusion
(epinephrine or norepinephrine)
84 (88%) 82 (90%) 155 (89%)
Dosage of vasopressors (epinephrine + norepinephrine),
μg/Kg/min
0.3 0.26 0.40
(0.09 to 0.51) (0.12 to 0.38) (0.13 to 0.66)
Patients treated with dobutamine before inclusion
3 (3%) 3 (3%) 10 (6%)
Time between severe sepsis identification and
inclusion, minutes
482 396 468
(220 to 510) (40 to 847) (188 to 696)
Time between ICU admission and inclusion, minutes
185 246 206
(53 to 317) (92 to 400) (97 to 315)
Time between satisfaction of inclusion criteria and
inclusion, minutes
231 161 185
(110 to 352) (60 to 262) (93 to 277)
Continuous variables are expressed as median and IQR, and categorical variables as number (%).
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The main finding of our study is that more than one
quarter of septic patients had ScvO2 < 70% in the first
hours after ICU admission. Furthermore, low ScvO2 in
the first hours of ICU admission (and/or 6 hours later)
was independently associated with 28-day mortality. These
data suggest that one quarter of septic patients admitted
to the ICU could be candidates for ICU protocol-based
therapy targeting ScvO2.Prevalence of low ScvO2
In the present multicentre study, using ScvO2 measure-
ments planned as early as possible in routine care, we
report a 27% prevalence of low ScvO2 (<70%). This
value is below the 40% to 50% prevalence reported in
the few, small sized, available prospective studies per-
formed to date in the ICU [9,10]. These studies analysed
selected patients: one study analysed only half of the pa-
tients with lactate above 3 mmol/L enrolled in a com-
parative therapeutic trial [9], and the other study
excluded patients with malignancy [10]. However, the
27% prevalence of low ScvO2 we observed in our study
with few exclusion criteria represents a non negligible
proportion of septic patients and does not support theview that low ScvO2 is uncommon after admission to
the ICU [5-8].
Importantly, even when classic clinical endpoints of
initial resuscitation were achieved (mean blood pressure
(BP) >65 mmHg, central venous pressure (CVP) > 8 mmHg
and urine output >0.5/ml/Kg) low ScvO2 could not be
ruled out as it was observed in one third of our apparently
resuscitated patients. Furthermore, arterial lactate also
misclassified patients in their low/high contemporaneous
ScvO2: the prevalence of ScvO2 < 70% was similar in
the case of lactate above or below the median value of
2.2 mmol/L (29% versus 33%; P = 0.3). This underlines
that ScvO2 measurement is not interchangeable with
these routine clinical and biological data.
Association between low ScvO2 and outcome
As expected, the SAPSII score and the arterial lactate
consistently appeared as powerful predictors of day-28
death. Independently of these two well-known predictors
[24,26], low initial ScvO2 was also consistently linked to
day-28 mortality. To the best of our knowledge, this has
never been previously shown in either emergency de-
partment or ICU studies. Of note, our study was not de-
signed to assess whether the link between low ScvO2
and mortality is a causal relationship.
Table 3 Logistic regression analysis of 28-day mortality in 363 septic patients, with initial ScvO2 value below 70%
adjusted for the other confounders
Covariablesa Adjusted odds ratiob 95% CI P-value
SAPSII (for each 1 point increase) 1.05 1.03, 1.07 <0.00001
Initial ScvO2 < 70% 3. 60 1.76, 7.36 0.0004
Arterial lactate (for each 1 mmol/L increase) 1.18 1.06, 1.32 0.002
Initial arterial partial pressure in CO2 (for each 1 mmHg increase) 1.04 1.01, 1.06 0.003
McCabe class 1 (versus class 0) 2.58 1.31, 5.10 0.006
Abdominal sepsis 2.56 1.25, 5.23 0.010
McCabe class 2 (versus class 0) 3.09 1.24, 7.72 0.016
Male gender 2.14 1.11, 4.13 0.022
Initial body temperature (for each 1C° increase) 0.78 0.62, 0.98 0.031
Exposure to ACE inhibitors or ARB in the past 48 hours 0.50 0.26, 0.98 0.044
aAll covariables entered in the model were variables linked to day-28 mortality with P <0.05 on univariate analysis, and selected using the backward method.
bFor each continuous covariable odds ratios are given per each unit of the given covariable. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor
blockers; SAPSII, Simplified acute physiology score; ScvO2, central venous oxygen saturation.
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One quarter of our septic patients had low ScvO2 in the
first hours of ICU admission and this was associated
with poor outcome. This was also the case for persisting
low ScvO2 (at 6 hours after the first measurement).
These patients could be candidates for ICU protocol-
based therapy targeting the ScvO2 in addition to routine
initial care. The choice between lactate-guided, ScvO2-
guided therapy, or between both, is still under debate
[27]. In emergency department septic patients, there
is no significant difference in patients’ outcomes when
managed either with lactate-guided or ScvO2-guided
therapy [28]. Interestingly, our results suggest that, ra-
ther than choosing one of these measurements, ScvO2
should be tested in combination with lactate monitoring
because low ScvO2 may be present or persist even in
the case of low lactate, or in the case of satisfactory lac-
tate clearance (see Figure 3 and Additional file 6). This
later finding was also observed in studies performed in
emergency department patients in the very early phase
of resuscitation: Arnold et al. [29] have shown that 15%
of patients with good lactate clearance and 21% of pa-
tients with poor lactate clearance had ScvO2 < 70%; in
the study by Jones et al. [28], an interventional, random-
ized trial comparing lactate clearance or ScvO2 > 70% as
therapeutic targets, the proportion of patients who did
not have normalized ScvO2 was 19% in both groups.
This proportion is lower than the one we observed but
may not reflect what happens in real conditions, as re-
suscitation was performed per protocol for the purpose
of the randomized trial. For their part, Jansen et al. [9]
compared usual care and protocol-based therapy with
lactate clearance as a target in an ICU population of
septic patients, and showed that at 6 hours, 33% of pa-
tients in the intervention group still had ScvO2 < 70%
while more than 40% had lactate clearance >20%.Although these findings are consistent with ours, once
again they may not reflect the real-life conditions as the
patients were treated according to a rigorous and com-
plex protocol. Therefore, to our knowledge, our study is
the first to show that ScvO2 and lactate may show non
parallel evolutions in septic patients cared for in the ICU
in real-life conditions.
The usefulness of protocol-based resuscitation including
the normalization of ScvO2 has been recently challenged
by the ProCESS trial [30], a randomized trial conducted in
emergency departments in the very early phase of resusci-
tation of septic patients. This study showed no advantage
in terms of survival with the protocol-based therapy in-
cluding the normalization of ScvO2 as compared to usual
care [30]. Of note, the ProCESS trial population was quite
different from that we studied in our work, in which we
estimated the prevalence of ScvO2 and of persisting ScvO2
in ICU patients, after the initial phase of resuscitation. On
the other hand, in 1995 Gattinoni et al. [31] also showed
that therapy aimed at normalizing the SvO2 value did not
lead to better outcome than standard care in a general
population of critically ill patients. Their results cannot be
transposed to our study population as they included fewer
than 25% of septic patients, and included them more than
48 hours after ICU admission [31], a time frame quite dif-
ferent from that used for inclusion in our work. For these
reasons we believe it is premature to abandon the concept
of normalization of ScvO2 in severely septic patients ad-
mitted to the ICU for whom low ScvO2 cannot be
neglected, given its association with increased day-28 mor-
tality. Further studies are required to precisely identify
which ICU patients would benefit from therapeutic strat-
egies aimed at ScvO2 normalization.
The LOWESS plot (see Additional file 4) used to iden-
tify cutoff values of initial ScvO2 illustrates that below
ScvO2 of 75%, the lower the ScvO2 the lower was the
Figure 2 (See legend on next page.)
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Figure 2 Forest plot for subgroup analysis. aAll cutoff values provided in the figure for demographic, clinical or laboratory variables are
median values calculated on the whole study population. bSequential organ failure assessment (SOFA) score is the highest value during the first
24 hours after enrollment. cWith the use of a cutoff of 2 mmol/L for lactate, the odds ratio for day-28 death (OR) was 1.29 (0.54, 3.05) in the case
of lactate >2 mmol/L, and 4.59 (1.79, 11.84) in the case of lactate ≤2 mmol/L. dVasopressor dose = continuous intravenous (iv) norepinephrine
dose plus continuous iv epinephrine dose. eLeft ventricular ejection fraction assessed by transthoracic echocardiography before 24 hours after
enrollment. fHaemoglobin concentration was taken into account only if measured between 6 hours before and 6 hours after enrollment. SAPSII,
Simplified acute physiology score; ScvO2, central venous oxygen saturation.
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day-28 mortality in our multivariate analysis. This cutoff
of 75% for worse outcome in our septic patients is
higher than that found in cardiac failure patients [32,33].
This is consistent with the physiopathology of septic
shock in which microcirculatory shunts lead to intra-
organ oxygen extraction impairment that necessitates
maintaining a high level of oxygen delivery to ensure ad-
equate organ oxygen uptake [34]. Beyond the confirm-
ation that ScvO2 of 70% is an important threshold for
patient outcome, our study also suggests that, in septic
patients, ScvO2 of 75% could be an even more relevant
target that best ensures that overall tissue oxygenation
is adequate in the context of septic oxygen extraction im-
pairment. However, the thresholds of ScvO2 that could be
proposed after the visual inspection of the LOWESS plot
were statistically estimated cutoff values in the entire study
population that may not apply at the individual level.
Therefore, ScvO2 value of 67% for instance does notFigure 3 Survival curve and death rate (%) at day 28 according to ini
The left part of the figure shows survival curves in four patients’ subgroup
ScvO2. The right part of the figure shows the day-28 death rate in each su
number of patients in each subgroup. aUnadjusted pair comparison of su
significant on log-rank test. bThere was no significant difference in crude
However, there was a significant global trend towards higher death rate f
with high lactate and low ScvO2 (P <0.001, Cochran-Armitage test).necessarily place a given patient in a dangerous condition,
and conversely an ScvO2 of 73% should not be seen as ne-
cessarily reassuring. In fact each individual patient prob-
ably has his/her own threshold from which it could be
dangerous to deviate, depending on how his/her tissues
are trained to extract oxygen in situations of high oxy-
gen demand [35] or insufficient oxygen transport, and
depending on the intensity of the microcirculatory
shunts [36] linked to the severity of the sepsis process. In
relation with this later issue, high values of ScvO2 may re-
flect the intensity of the microcirculatory derangements
caused by sepsis. Some studies have suggested that either
ScvO2 higher than 80% within the first 3 days in the ICU
[37] or ScvO2 higher than 90% in the emergency depart-
ment [38], were markers of poor prognosis. Indeed, al-
though our study was underpowered to specifically
examine the role of high values of ScvO2, we also observed
that, beyond the threshold of 75%, the higher the ScvO2, the
lower was the survival (see Additional file 4).tial lactate level and central venous oxygen saturation (ScvO2).
s according to their initial zero hours (H0) lactate concentration and
bgroup. Numbers inside the bars are number of non survivors/total
rvival curves between the different subgroups were not statistically
death rate at day-28 among the four groups (chi-squared test).
rom the condition with normal lactate and ScvO2 to the condition
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First, this study was not designed to seek for the reasons of
low ScvO2. Since we have not systematically measured car-
diac output, we cannot distinguish between the roles played
by too-low oxygen delivery on the one hand and too-high
oxygen demand on the other hand. Second, our study was
clearly underpowered to draw conclusions about the signifi-
cance of high ScvO2 values. Third, in view of our inclusion
rate, selection bias cannot be definitely ruled out. However,
patients were not selected on the basis of the variable of
interest (ScvO2), which was not known during the screen-
ing/enrolment process. Additionally, enrolled and non en-
rolled patients’ characteristics were similar (see Additional
file 2). Moreover, as shown in Additional file 2, the propor-
tion of patients with low ScvO2 consistently ranged from
around 24% to 36% in subgroups of patients classified ac-
cording to their cardiac or respiratory status, or to the tim-
ing and intensity of therapeutic interventions performed
before inclusion. Fourth, ScvO2 was not measured by the
same method in all participating centres, as four used
standard blood gas analysers and six used co-oximeters.
This might have distorted the accurate determination of
cutoff values of ScvO2, because the limits of agreement
between both methods are wide [39]. However, this does
not impair the general interpretation of our results as a
majority (265/363) of the included patients had ScvO2
measured by co-oximetry and the link between low ScvO2
and day-28 mortality remained statistically significant in
this patient subgroup.
Conclusion
Our study demonstrated that, in septic patients, low levels of
ScvO2 in the first hours of ICU admission were frequent
(<70% for more than one quarter), even when clinical resus-
citation endpoints are achieved and even when arterial lactate
was normal. Importantly, ScvO2 in the first hours of ICU ad-
mission and/or six hours later was linked to day-28 mortality.
Key messages
 In septic shock patients, low ScvO2 (<70%) is
common in the first hours of admission to the ICU
 In septic shock patients, low ScvO2 (<70%) in the
first hours of admission to the ICU is associated
with increased day-28 mortality
 In addition to usual care, ICU protocol-based
therapy targeting ScvO2 may be tested in controlled
trials in septic patients with low or persisting low
ScvO2 in the first hours of ICU admission
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